GlaxoSmithKline studies the efficacy of EndoBarrier

New findings released at Digestive Disease Week '14

GlaxoSmithKline have researched postoperative bile acid levels in patients with severe obesity, with and without type 2 diabetes, and how it may provide similar results to the Roux-en-Y gastric bypass.

Findings show that the EndoBarrier induces significant changes in bile acid levels. It is believed that this research starts to provide an explanation for the excessive weight loss seen with the EndoBarrier therapy for patients with Type 2 Diabetes and Obesity. Further exploration is needed and GSK support this continued investigation. 

Read more on the EndoBarrier here and the full article on the Wall Street Journal.

« Back to News

Latest News

Well done Team!

Customer Satisfaction Survey 2019: THE RESULTS

Continue Reading